{'fraction_non_alphanumeric': 0.05733662145499383, 'fraction_numerical': 0.058569667077681874, 'mean_word_length': 4.392026578073089, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The evaluation of effi cacy of intravitreal afl ibercept and bevacizumab in the treatment of zone i retinopathy of prematurity

Purpose: To evaluate the clinical outcomes of the patients who received intravitreal afl ibercept (IVA) or intravitreal bevacizumab (IVB) due to zone I retinopathy of prematurity (ROP). Materials and Methods: In this study, the data of patients who received IVA or IVB due to aggressive posterior ROP (APROP) or type 1 ROP in zone I were retrospectively reviewed. Patients’ birth weights (BW), gestational age (GA), postmenstrual age during treatment (PMA), regression and recurrence rates, and additional treatments were recorded. Results: The study included 33 patients who were treated due to APROP or type 1 ROP in zone I. The IVA group with 22 eyes of 11 patients (Group 1) and the IVB group with 42 eyes 22 patients (Group 2). The mean BW of the patients were 932.7±330 grams and 1117.0±578 grams (p=0.07) and the mean GA values were 26.6±2.3 weeks and 28±3.5 weeks (p=0.83) in Group 1 and Group 2, respectively. The follow-up duration was 16.5±2.3 months and 8.0±2.6 months in Group 1 and Group 2, respectively (p=0.000). The PMA at treatment was applied was 33.5 weeks in Group 1 and 34.2 weeks in Group 2 (p=0.146). Regression rate after initial treatment was 100% in Group 1 and 88.0% in Group 2 (p=0.046). The rate of additional treatment due to recurrence was 27.2% and 23.8%, respectively (p=0.537). Conclusion: ROP in zone I can be successfully treated with IVA and IVB. However, requiring additional treatment due to recurrence at high rates is a disadvantage of these therapies.